Oxford Biomedica Past Earnings Performance

Past criteria checks 0/6

Oxford Biomedica's earnings have been declining at an average annual rate of -62.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9.6% per year.

Key information

-62.7%

Earnings growth rate

-57.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate9.6%
Return on equity-235.7%
Net Margin-146.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oxford Biomedica makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:OXOA Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2497-1422581
31 Mar 2493-1502592
31 Dec 2390-15725103
30 Sep 23104-11025110
30 Jun 23119-6225117
31 Mar 23130-5024106
31 Dec 22140-392395
30 Sep 22133-322182
30 Jun 22126-251969
31 Mar 22134-31758
31 Dec 21143191447
30 Sep 21139191341
30 Jun 21135191334
31 Mar 2111161237
31 Dec 2088-61140
30 Sep 2077-91239
30 Jun 2066-131338
31 Mar 2065-141234
31 Dec 1964-161230
30 Sep 1964-121026
30 Jun 1964-8922
31 Mar 19650820
31 Dec 18678719
30 Sep 18624722
30 Jun 18570725
31 Mar 1847-5723
31 Dec 1738-9722
30 Sep 1734-10622
30 Jun 1731-11522
31 Mar 1729-14623
31 Dec 1628-17624
30 Sep 1626-16724
30 Jun 1624-16824
31 Mar 1620-15722
31 Dec 1516-13720
30 Sep 1515-12620
30 Jun 1513-10519
31 Mar 1513-9418
31 Dec 1414-9417
30 Sep 1411-9415
30 Jun 148-10314
31 Mar 147-11314
31 Dec 135-11314

Quality Earnings: OXOA is currently unprofitable.

Growing Profit Margin: OXOA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OXOA is unprofitable, and losses have increased over the past 5 years at a rate of 62.7% per year.

Accelerating Growth: Unable to compare OXOA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXOA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: OXOA has a negative Return on Equity (-235.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford Biomedica plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rick BienkowskiCantor Fitzgerald & Co.
Susie JanaEdison Investment Research
Jens LindqvistInvestec Bank plc (UK)